
Actnowfordiabetes
14/11/2022
employees
Over 150 countries where the
Group’s medicines are distributed
Over 20% of revenue from
brand-name medicines invested
in R&D each year
euros in revenue in 2021/2022
including €3.7 billion for brand-name medicines and
€1.2 billion for generic activities
oncology, neuroscience,
immuno-inflammation,
and cardiometabolism